NEUROCRINE BIOSCIENCES INC (NBIX) Cash flow
Market cap
$12.8B
P/E ratio
27.3x
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Stock-based compensation | 3 | 5 | 7 | 10 | 28 | 28 | 43 | 58 | 75 | 100 | 134 | 173 | 194 | 196 | 218 |
| Cash from operations | -1 | -35 | -30 | -47 | -38 | -106 | -94 | 101 | 152 | 229 | 257 | 339 | 390 | 595 | 783 |
| Capital expenditures | -1 | -1 | -1 | -2 | -2 | -4 | -7 | -25 | -15 | -11 | -23 | -16 | -28 | -38 | -34 |
| Cash from investing | -4 | -35 | 5 | -105 | -196 | 113 | -251 | -243 | -211 | 4 | -130 | -177 | -467 | -127 | -264 |
| Repurchases of common stock | - | - | - | - | - | - | - | - | - | - | - | - | - | 300 | 168 |
| Cash from financing | 0 | 84 | 5 | 139 | 277 | 2 | 517 | 30 | 27 | -158 | 27 | -234 | 65 | -487 | -38 |
| Free cash flow | |||||||||||||||
| FCF margin (%) | - | - | - | - | - | - |